Tesamorelin
πΉ What is Tesamorelin?
Class: Synthetic Growth Hormone-Releasing Hormone (GHRH) analog; stabilized to resist degradation and prolong half-life. Mechanism:
- Stimulates the pituitary gland to increase endogenous growth hormone (GH) release.
- Enhances IGF-1 production, promoting anabolic effects, lipolysis, and tissue repair.
- Regulates body composition, primarily reducing visceral adipose tissue.
- Indirectly supports metabolic function, mitochondrial activity, and lipid metabolism.
Primary focus:
- Reduction of visceral fat (FDA-approved for HIV-associated lipodystrophy).
- Anabolic support and lean mass maintenance.
- Metabolic optimization (lipid profile and glucose homeostasis).
- Support for tissue repair and recovery via GH/IGF-1 signaling.
πΉ Oral Dosage
- Poor oral bioavailability β oral administration is ineffective.
πΉ Injectable / Subcutaneous Dosage (most common) Range:
- 2 mg SC once daily (clinical standard for HIV lipodystrophy).
- Research and biohacking communities sometimes use 1β2 mg/day based on goals.
Frequency:
- Daily injection recommended to mimic natural GH pulsatility.
Rationale: Direct SC injection provides consistent absorption and predictable GH stimulation.
πΉ Cycle Length
- Clinical studies: 26 weeks (6 months) to see measurable visceral fat reduction.
- Wellness/anti-aging: cycles of 8β12 weeks are sometimes used, followed by evaluation of body composition and IGF-1 levels.
πΉ Optimal Dosing Window
- Fasted, Evening or bedtime is preferred to align with natural GH peaks during sleep.
- Can be split or adjusted based on GH/IGF-1 monitoring.
β Educational Integration Example Example protocol: 2 mg SC daily at bedtime for 12 weeks. Paired with: CJC-1295/Ipamorelin 100 mcg each in the morning + proper nutrition and resistance training. Rationale: Mimics physiologic GH rhythm, supports lean mass, fat loss, and tissue recovery.
πΉ Stacking Strategy (Educational / Complementary) Since Tesamorelin primarily stimulates GH and IGF-1 pathways, stacks often include GH secretagogues, metabolic enhancers, and recovery peptides: πΈ GH & Anabolic Support
- CJC-1295 (with or without DAC) / Ipamorelin / GHRP-2/6 β synergize to maximize endogenous GH release.
- IGF-1 LR3 or Mechano Growth Factor (MGF) β tissue repair and muscle regeneration.
πΈ Metabolic & Fat Loss Support
- MOTS-c, AICAR, L-Carnitine, Lipo-C β enhance fatty acid oxidation and mitochondrial efficiency.
- Cardarine (GW-501516) β endurance and lipid metabolism support.
πΈ Recovery & Longevity
- NADβΊ / Epitalon / FOXO4-DRI β maintain mitochondrial function, DNA repair, and anti-aging support during GH-focused cycles.
Rationale: Tesamorelin provides the central GH drive, while stacks target fat loss, muscle repair, metabolic efficiency, and overall resilience.
β οΈ Safety Notes
- Side effects: mild edema, joint pain, injection site irritation, increased IGF-1 levels.
- Monitor IGF-1 to avoid supraphysiologic levels.
- Contraindicated in active malignancy, uncontrolled diabetes, or hypersensitivity to peptides.
- Long-term safety outside clinical settings is not well established.
Studied in Humans? Yes
FDA Approved? Yes
Allowed for 503a Compounding Pharmacy? No
Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.